Fig. 3From: Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisForest plots of pooled HRs of PFS and OS between the wild type and the TP53 mutation patients based on TKIs therapy (a) PFS; (b) OS. Abbreviations: HR hazard ratio, PFS progression-free survival, OS overall survival, TP53 tumor protein 53, TKI tyrosine kinase inhibitor, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinaseBack to article page